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A B S T R A C T
Background
Crimean Congo haemorrhagic fever (CCHF) is a tick-borne disease that occurs in parts of Asia, Europe and Africa. Since 2000 the
infection has caused epidemics in Turkey, Iran, Russia, Uganda and Pakistan. Good-quality general supportive medical care helps reduce
mortality. There is uncertainty and controversy about treating CCHF with the antiviral drug ribavirin.
Objectives
To assess the effects of ribavirin for treating people with Crimean Congo haemorrhagic fever.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Central Register of Controlled Trials (CENTRAL);
MEDLINE (PubMed); Embase (OVID); Science Citation Index-Expanded, Social Sciences Citation index, conference proceedings
(Web of Science); and CINAHL (EBSCOHost). We also searched the WHO International Clinical Trials Registry Platform (ICTRP)
and ClinicalTrials.gov for trials in progress. We conducted all searches up to 16 October 2017. We also contacted experts in the field
and obtained further studies from these sources.
Selection criteria
We evaluated studies assessing the use of ribavirin in people with suspected or confirmed Crimean Congo haemorrhagic fever. We
included randomised control trials (RCTs); non-randomised studies (NRSs) that included more than 10 participants designed as cohort
studies with comparators; and case-control studies.
Data collection and analysis
Two review authors assessed eligibility, risk of bias, and extracted data. For non-randomized studies we used the ROBINS-I tool to assess
risk of bias. The main effects analysis included all studies where we judged the risk of bias to be low, moderate or high. We summarized
dichotomous outcomes using risk ratios (RRs) and continuous outcomes using mean differences (MDs), and used meta-analyses where
appropriate. We carried out a subsidiary appraisal and analysis of studies with critical risk of bias for the primary outcome, as these are
often cited to support using ribavirin.
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Main results
For the main effects analysis, five studies met our inclusion criteria: one RCT with 136 participants and four non-randomized studies
with 612 participants. We excluded 18 non-randomized studies with critical risk of bias, where none had attempted to control for
confounding.
We do not know if ribavirin reduces mortality (1 RCT; RR 1.13, 95% confidence interval (CI) 0.29 to 4.32; 136 participants; very
low-certainty evidence; 3 non-randomized studies; RR 0.72, 95% CI 0.41 to 1.28; 549 participants; very low-certainty evidence). We
do not know if ribavirin reduces the length of stay in hospital (1 RCT: mean difference (MD) 0.70 days, 95% CI -0.39 to 1.79; 136
participants; and 1 non-randomized study: MD -0.80, 95% CI -2.70 to 1.10; 50 participants; very low-certainty evidence). We do not
know if it reduces the risk of patients needing platelet transfusions (1 RCT: RR 1.23, 95% CI 0.77 to 1.96; 136 participants; very low-
certainty evidence). For adverse effects (including haemolytic anaemia and a need to discontinue treatment), we do not know whether
there is an increased risk with ribavirin in people with CCHF as data are insufficient.
We do not know if adding ribavirin to early supportive care improves outcomes. One non-randomized study assessed mortality in
people receiving ribavirin and supportive care within four days or less from symptom onset compared to after four days since symptom
onset: mortality was lower in the group receiving early supportive care and ribavirin, but it is not possible to distinguish between the
effects of ribavirin and early supportive medical care alone.
In the subsidiary analysis, 18 studies compared people receiving ribavirin with those not receiving ribavirin. All had a critical risk of
bias due to confounding, reflected in the mortality point estimates favouring ribavirin.
Authors’ conclusions
We do not know if ribavirin is effective for treating Crimean Congo haemorrhagic fever. Non-randomized studies are often cited as
evidence of an effect, but the risk of bias in these studies is high.
P L A I N L A N G U A G E S U M M A R Y
Ribavirin for treating Crimean Congo haemorrhagic fever
What is the aim of this review?
The aim of this Cochrane review is to find out if ribavirin is an effective treatment for Crimean Congo haemorrhagic fever. Cochrane
researchers collected and analysed all relevant studies to answer this question. We found 23 studies. We include five studies in this
review that helped answer the question. We analysed the other 18 studies to help describe the limitations of the evidence.
Key messages
There is insufficient reliable evidence to showwhether ribavirin is effective in treatingCrimeanCongo haemorrhagic fever. A randomised
clinical trial could help answer this question.
What was studied in the review?
Crimean Congo haemorrhagic fever (CCHF) is an infection spread by tick bites. It has become more common in the last 15 years,
particularly in Turkey and parts of Eastern Europe. CCHF can be life threatening. The most important way of caring for people who
are seriously unwell with CCHF is to monitor them closely in hospital and give them any fluid or blood products they may need.
Ribavirin is an antiviral drug that some doctors use to treat CCHF. It is widely available and is normally taken by mouth. There is
debate over whether ribavirin is needed to treat CCHF; some argue that it is an effective treatment, or helps if given early, whilst others
say that it has no effect, in terms of the risk of death, the length of time needed in hospital, and the extent of harm from the drug itself.
Overall, the study designs did not take into account factors other than taking ribavirin that could result in better outcomes in the
intervention group, including how ill the patient was when diagnosed, or when good supportive medical care was started. This made
any association between ribavirin and lower mortality problematic.
We found five studies that took into account important factors that could confound the risk of dying with whether or not a patient
received ribavirin. These include how sick the study participants were, what other care they received, and how long after they became
sick they receivedmedical care. All included studies were conducted in Turkey and Iran, and compared people with CCHF who received
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ribavirin and supportive care to those who received supportive care alone. We looked at five different outcomes relating to ribavirin use
in CCHF, and found that there is insufficient reliable evidence to determine whether ribavirin is effective.
How up to date is the review?
The review authors searched for studies that had been published up to 16 October 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Ribavirin compared to no ribavirin for Crimean Congo haemorrhagic fever
Patient or population: people diagnosed with suspected or conf irmed Crimean Congo haemorrhagic fever
Setting: global
Intervention: ribavirin
Comparison: no ribavirin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with no ribavirin Risk with ribavirin
Mortality 56 per 1000 63 per 1000
(16 to 240)
RR 1.13
(0.29 to 4.32)
136
(1 RCT)1
⊕©©©
VERY LOW2,3
-
Length of hospital stay
(days)
The mean length of hospital stay in 1 RCT was
0.7 days longer in the experimental group (0.39
days fewer to 1.79 days longer)
- 136
(1 RCT)4
⊕©©©
VERY LOW2,3
-
Requirement for trans-
fusion (platelets)
306 per 1000 376 per 1000
(235 to 599)
RR 1.23
(0.77 to 1.96)
136
(1 RCT)
⊕©©©
VERY LOW2,3
-
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RCT : randomised controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1In addit ion there were three non-randomized studies (m ixed retrospect ive and prospect ive cohort ; single arm cohort with
historical control; matched case series) with serious risk of bias (ROBINS-I), providing an est imate of RR 0.59, 95% CI 0.27
to 1.27; 549 part icipants; very low-certainty evidence).
2Downgraded one level for risk of bias: one RCT with no descript ion of randomisat ion or concealment of allocat ion.
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3Downgraded two levels for imprecision. Few events and wide CI containing appreciable benef it and harm.
4In addit ion one non-randomized study (matched case series) with serious risk of bias (ROBINS-I) providing an est imate of
0.8 days fewer in the experimental group (2.7 days fewer to 1.1 days longer); very low-certainty evidence.
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B A C K G R O U N D
Description of the condition
Crimean Congo haemorrhagic fever (CCHF) is a tick-borne viral
disease. The virus that causes CCHF is a Nairovirus, a member
of the Bunyaviridiae family. The most common vectors of the
disease are Hyalomma ticks, which spread the disease and also act
as a disease reservoir. CCHF is found in Africa, Eastern Europe,
the Middle East, and Asia, with further occasional cases in other
European countries such as Spain and Greece (Hoogstraal 1979;
Zapata 2014;GarcíaRada 2016). In recent years, CCHF incidence
has been increasing in several areas worldwide (Zapata 2014).
The disease starts with a headache, fever, abdominal pain, muscu-
loskeletal pain, and nausea. Over the next few days this is followed
by gastro-intestinal symptoms, including vomiting, diarrhoea, and
haemorrhagic rash. After three to five days, a few patients progress
to severe microvascular instability and the haemorrhagic phase of
the illness, which is usually manifested first by a petechial rash
followed by ecchymosis and bleeding. As the disease progresses
into the second week, bleeding can worsen and become more se-
vere, resultingmost commonly in haemorrhage under the skin and
within the abdomen. Death rates in people infected can reach up
to 50% (Hoogstraal 1979). In endemic areas where high-quality
supportive care and access to diagnostics are offered, death rates
can be as low as 5% (Leblebicioglu 2016b).
Many infections occur without symptoms and some estimates sug-
gest this occurs in most infections (Bodur 2012). CCHF severity
varies in people who are clinically unwell. Different scores to as-
sess severity are used but it remains unclear what proportion of all
infections are severe (Swanepoel 1987; Dokuzoguz 2013).
Infection in people is usually due to a tick bite or by contact with
infected bodily fluids from humans or animals (Ergönül 2006b).
Those at highest risk of contracting the virus are people who work
outdoors in CCHF-endemic areas, those who work with large
domestic animals, and healthcare workers (Whitehouse 2004).
CCHF has been linked to reservoirs such as sheep, goats, hedge-
hogs, and hares (Causey 1970; Saluzzo 1985; Yen 1985; Shepherd
1987). Human-to-human transmission occurs within families and
in healthcare settings, including nosocomial outbreaks. The great-
est risk of nosocomial exposure is from splash exposures and nee-
dle stick injuries (Conger 2015; Leblebicioglu 2016a). Case series
studies also suggest that in rare cases airborne transmission from
ventilated patients may also occur (Pshenichnaya 2015). Case re-
ports suggest possible sexual transmission, although there is no
published evidence of the virus being present in seminal or vagi-
nal fluid (Pshenichnaya 2016). The virus is also transmitted from
person to person by infected bodily fluids, and is highly infectious.
The disease may become more important in future years because
of changes to the habitat of the Hyalomma tick vector, which is
due in part to changes in the rural landscape from large diffuse
habitats to smaller habitats. This is shown to lead to densely-
populated habitats for the tick vector, which is associated with
increasing incidence of the disease (Estrada-Peña 2007). Given
the high mortality of patients, the lack of a widely-available viable
vaccine (Dowall 2016), and an emerging pattern of spread with
multiple countries reporting re-emergence of epidemics or new
cases (Messina 2015), CCHF should be considered a potential
threat to public health.
Description of the intervention
Supportive medical care underpins CCHF treatment, and use
of fluids, good nursing care, and blood products in response
to changes in the blood’s ability to clot are key components
(Leblecioglu 2012). Previous attempts at therapeutic regimens
have explored intravenous (IV) immunoglobulin (Ig) isolated from
horses (Hoogstraal 1979), and from recovered patients (Vassilenko
1990), but these are not currently widely used.
Ribavirin is commonly used with interferon to treat people who
have hepatitis C, and is used alone in treating people who have
Lassa fever (Debing 2013). Ribavirin is also used in healthcare
settings as a form of post-exposure prophylaxis for those exposed
to CCHF (Leblebicioglu 2016a). Non-randomized studies show
that it could be effective in treating cases of CCHF (Fisher-Hoch
1995; Mardani 2003; Dokuzoguz 2013), although this has been
debated (Kalin 2014; Leblebicioglu 2016a). One such idea is that
administration of ribavirin early in the disease, when it appears to
be at its most effective, may be a promising approach (Dokuzoguz
2013;Ozbey 2014). This fits with the known course of the disease,
where the virus ismost commonly only present in the bloodwithin
the first week following onset of CCHF symptoms (Bente 2013).
Ribavirin has adverse effects, and, as well as the questions about
its efficacy, clinicians debate whether or not to risk using the
drug (Ceylan 2013; Oflaz 2015). Some of the adverse effects in-
clude risks of haemolysis, arrhythmia, bone marrow suppression,
and deranged liver function (EMA 2015). Two previous system-
atic reviews have shown no clear benefit of ribavirin in people
with CCHF, although the available evidence is limited mainly to
confounded non-randomized data (Soares-Weiser 2010; Ascioglu
2011).
No alternative therapy has been proposed as the mainstay of ther-
apeutic treatment. Although newer drugs, such as favipiravir, have
shown promise in vitro (Oestereich 2014), widespread adoption
of new therapies is years away. Current treatment guidelines and
case definitions vary from region to region and from country to
country (DoH South Africa 2014; Kalin 2014).
How the intervention might work
Ribavirin is a synthetic nucleoside that is active against a broad
spectrum of DNA and RNA viruses (Sidwell 1972). It is one of
few drugs shown to be active against CCHF in vitro (Watts 1989).
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Ribavirin can be given in hospital settings either intravenously
or orally, according to World Health Organization (WHO) rec-
ommendations (WHO2015). National guidelines from countries
such as South Africa (DoH South Africa 2014), India (NCDC
2011), and Pakistan (NIH 2013) recommend prompt treatment
with ribavirin following diagnosis of CCHF. However, these rec-
ommendations for management are not based on a robust evi-
dence base (Soares-Weiser 2010). CCHF can be mild or more se-
vere, and it is often not deemed necessary to treat mild cases of
the disease (Ergönül 2004). Questions remain about the overall
benefits of ribavirin, how long after the onset of symptoms it is
most effective, and whether it is more or less effective in severe
cases (Ergönül 2006b; Dokuzoguz 2013; Leblebicioglu 2016b).
Why it is important to do this review
The controversy surrounding ribavirin use and the benefits of a
widely-available treatment for CCHF mean an up-to-date review
of the existing evidence is required. There are mixed views on
whether to treat CCHFwith ribavirin, given the uncertainty about
the balance between potential but unproven benefit and known
risks of the drug (Kalin 2014). It is therefore important to use
the data available to address whether ribavirin reduces the number
of deaths from a lethal disease, whilst assessing the possibility of
harm from serious, life-threatening adverse effects.
O B J E C T I V E S
To assess the effects of ribavirin for treating people with Crimean
Congo haemorrhagic fever (CCHF).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included the following types of study:
• Randomized controlled trials (RCTs), quasi-RCTs, and
non-randomized controlled studies of ribavirin compared to no
ribavirin; also studies comparing early versus late administration
of ribavirin
• Cohort studies with ribavirin compared to no ribavirin, and
studies comparing early versus late administration of ribavirin
(prospective and retrospective, with more than 10 participants).
• Case-control studies with ribavirin compared to no
ribavirin, and studies comparing early versus late administration
of ribavirin
Types of participants
Children or adults of any age with CCHF confirmed with a lab-
oratory test (immunoglobulin (Ig) or polymerase chain reaction
(PCR))
Types of interventions
Intervention
• Ribavirin (intravenous (IV) or oral)
• Early ribavirin (as defined in identified studies)
Control
• Supportive care only
• Late ribavirin (as defined by study authors)
We accepted co-interventions as long as the indication for the co-
intervention was consistent between groups, for example, admin-
istration of platelets according to homeostatic need.
Types of outcome measures
Primary outcomes
• Death (in hospital or 28 days post-admission)
Secondary outcomes
• Length of hospital stay (days)
• Requirement for transfusion (any blood products, including
platelets, fresh frozen plasma, packed red cells, or whole blood)
• Withdrawal of treatment due to serious adverse events
• Serious adverse events, as defined according to the accepted
US Food and Drug Administration (FDA) definition of: “if in
the view of the investigator or sponsor, the event results in any of
the following outcomes: death, life threatening adverse event,
inpatient hospitalizations, prolongation of existing
hospitalisation, disability or permanent damage, congenital
abnormality, required intervention to prevent permanent
impairment or other serious medical events” (FDA 2016).
Search methods for identification of studies
We tried to identify all relevant trials, regardless of language or pub-
lication status (published, unpublished, in press, and in progress).
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Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Dis-
easesGroup SpecializedRegister (16October 2017); theCochrane
Central Register of Controlled Trials (CENTRAL, Issue 9 of 12,
September 2017), published in the Cochrane Library; MED-
LINE (PubMed, 1966 to 16 October 2017); Embase (OVID,
1947 to 16 October 2017); Science Citation Index-Expanded,
Social Sciences Citation index, conference proceedings (Web of
Science, 1900 to 16 October 2017); and CINAHL (EBSCOHost
(1982 to 16 October 2017). We also searched the WHO Inter-
national Clinical Trials Registry Platform (ICTRP; www.who.int/
ictrp/en/) and ClinicalTrials.gov (clinicaltrials.gov/ct2/home) for
trials in progress, up to 16 October 2017, using “ribavirin” and
“CrimeanCongohaemorrhagic fever” or “CCHF” as search terms.
Searching other resources
We searched the reference lists of any relevant systematic reviews.
We contacted researchers in the field, requested information about
grey literature and ongoing studies from the WHO, and checked
reference lists of included studies.
Data collection and analysis
Selection of studies
Two review authors independently screened all citations and ab-
stracts identified in the search according to predefined inclusion
criteria. We obtained the full-text reports of all potentially eli-
gible studies or studies we were unclear about. Two review au-
thors independently screened these full-text articles, resolving any
disagreements through discussion and if necessary consulting a
third review author. We listed all studies excluded after full-text
assessment and their reasons for exclusion in the ‘Characteristics
of excluded studies’ table.
We included all unique studies in analyses; however, if there were
any studies at critical risk of bias we excluded them from the main
effects analyses. We included studies at critical risk of bias in a
subsidiary descriptive analysis, using non-overlapping samples as
described in Appendix 2.
Data extraction and management
One review author extracted data using pre tested data extraction
forms. A second review author cross-checked the extracted data.
We resolved any disagreements about data extraction by referring
to the study report and through discussion. We attempted to con-
tact the study authors where data were insufficient or missing.
We extracted data using a tool tailored for the inclusion criteria
described above, including the following information:
• Dose and method of administration (oral or IV)
• Adult or child populations
• Location
• Setting
• Design
• Study size
• Dates
• Death
• Length of hospital stay (days)
• Transfusion of blood products
• Serious adverse events
• Time since onset of symptoms (days) to treatment with
ribavirin or supportive care only
Assessment of risk of bias in included studies
Two review authors assessed the risks of bias of each included study,
resolving any disagreements through discussion and consulting a
third review author if necessary. For RCTs or quasi-RCTs, we used
theCochrane ‘Risk of bias’ tool for RCTs (Higgins 2011). For non-
randomized studies, we used the ROBINS-I tool (Risk Of Bias In
Non-randomized Studies - of Interventions) (Sterne 2016).
We assessed risks of bias through a hierarchy of domains, start-
ing with critical then serious, moderate, and low. If any domain
reached critical risk of bias we did not continue with the assess-
ment, as further evaluation would not influence how we assess the
certainty of the evidence.
As the risk of bias in the effect of an intervention may be different
for different outcomes, we made a ‘Risk of bias’ assessment for
each outcome.
Our full methods for using ROBINS-I are set out in Appendix 3.
For assessment of confounding we considered length of time from
onset of symptoms to receiving medical care or ribavirin, severity
of disease, historical controls rather than contemporary controls,
and quality of supportive care to be confounding domains. We
made the decision to define these as confounding factors based
on extensive debate in the literature (Ergonul 2009; Soares-Weiser
2010; Kalin 2014), alongside consultation with clinicians with ex-
perience of treating viral haemorrhagic fever and CCHF.We listed
co-interventions that could differ between intervention groups im-
pacting on outcomes as ‘quality of supportive care’.
TheROBINS-I tool recommends only includingnon-randomized
studies that are not classified as having critical risk of bias. For
our main effects analysis, we followed this approach. In addition,
there was a further set of studies which met the inclusion criteria
but which we classified as having critical risk of bias. As some of
these studies have traditionally been used as part of the evidence
base, we carried out a subsidiary descriptive analysis describing
these studies and their estimates of effect. We established a non-
overlapping sample and performed meta-analysis to describe the
effect of confounding.
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Measures of treatment effect
We analysed data using Review Manager 5 (RevMan 5) (RevMan
2014). For dichotomous outcomes, we presented analyses using
risk ratios (RRs) with their 95% confidence intervals (CIs). For
continuous data we used mean differences (MDs) with their 95%
CIs.
Unit of analysis issues
We did not identify any studies that used a cluster-randomized
design or multiple interventions. For our subsidiary descriptive
analysis of studies at critical risk of bias we established a non-
overlapping sample of studies using decision rules and methods
set out in Appendix 2.
If we had identified studies of a cluster design we would have only
used adjusted measures of effect. If the included study had not
performed any adjustment for clustering, we would have adjusted
the raw data ourselves, using an intracluster correlation coefficient
(ICC).
We did not identify any studies with multiple intervention arms,
but if we had we would have included data from these studies by
either combining treatment arms, or by splitting the control group
so that we only include participants once in the meta-analysis.
Dealing with missing data
We attempted to contact the study authors to obtain missing data
when the lack of reporting of necessary data restricted the use of
the study.
We applied no imputation measures for missing data.
In one study there was an unclear amount of missing data from an
analysis looking at the added benefit of corticosteroid use as well
as ribavirin (Dokuzoguz 2013). This occurred because the num-
ber of participants included in the analysis did not tally with the
explanation of how data were analysed in the text. These missing
data may have affected the adjusted odds ratio (OR) presented in
the study. We took this into account in the ‘Risk of bias’ assess-
ment, and it affected our decision not to present the adjusted es-
timate of effect; instead we presented a forest plot with the results
stratified by severity of diease. As the missing data did not affect
results relating to ribavirin and mortality, we did not classify the
study as being at critical risk of bias.
Assessment of heterogeneity
We examined the included studies to determine whether there was
heterogeneity in terms of co-intervention, level of supportive care
available, and risks of bias in the included studies.
We inspected forest plots to assess whether statistical heterogeneity
was present. We deemed CIs that did not overlap as an indication
of statistical heterogeneity. We also performed the Chi2 test using
a cut-off point of P < 0.10 to indicate statistical heterogeneity, and
we used the I2 statistic to quantify the heterogeneity. We inter-
preted the I2 statistic value according to guidance in the Cochrane
Handbook of Systematic Reviews of Interventions (Higgins 2011).
Assessment of reporting biases
If applicable, we intended to use funnel plot analysis or statisti-
cal tests (such as the Egger regression test), or both, to assess for
publication bias. We planned to perform funnel plot analysis if
there were more than 10 studies in any meta-analysis. As there
were fewer than 10 studies included in any of the effects analyses
we did not perform this test.
Data synthesis
In order to deal with non-standard study designs we have pre-
sented our main effects analysis by study design. We separated
study designs into different subgroups and did not pool results
across randomised and non-randomized subgroups. This included
RCTs, retrospective cohort studies, matched cohort studies and
historically-controlled cohort studies.
We stratified studies by their risk of bias in the descriptive analysis.
We did not include studies which we assessed as having critical
risk of bias in the main effects analysis. We performed a meta-
analysis of studies using the random-effects model; this was due
to varying study type, differences in populations and supportive
therapy available.
We examined those studies classified as being at critical risk of
bias in a subsidiary descriptive analysis that assessed the degree of
confounding. We assembled a non-overlapping sample, as set out
in Appendix 2.
One study (Dokuzoguz 2013) used a model to adjust for con-
founding of effect due to severity of disease. This resulted in an ad-
justed OR of 0.04 (95% CI 0.004 to 0.48). The small sample size,
the size of the adjusted effect, missing data from the corticosteroid
analysis, concerns about residual confounding due to time from
onset of symptoms to presentation to hospital/administration of
ribavirin, and the fact that the study analysed severely-ill patients
with gastro-intestinal haemorrhage “per protocol” and not by in-
tention-to-treat, meant that we took a conservative approach to
synthesis. We presented non-adjusted data from the study in the
main effects analysis, and the stratified data in a separate analysis
(Analysis 1.2).
We used the GRADE approach to assess the certainty of the evi-
dence, and created ‘Summary of findings’ tables and Evidence Pro-
files (GRADEpro 2015). Data from observational studies started
as low quality, but we intended to upgrade this to moderate or
high quality if the pooled estimates revealed a large effect size,
negligible concerns about confounders, or a strong dose-response
gradient.
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Subgroup analysis and investigation of heterogeneity
If unexplained heterogeneity occurred we intended to perform
subgroup analyses of the results, to assess whether the effect of
ribavirin was influenced by any of the following factors:
• Severity of symptoms: severe, moderate, mild
• Duration of treatment, presence of severe gastro-intestinal
symptoms, and route of administration
• Age (children versus adults). Children are defined as under
16 years of age.
We did not conduct subgroup analyses, because there were insuf-
ficient data to apply the prespecified subgroups in the primary
effects analysis.
Sensitivity analysis
If we had estimated an ICC to adjust the results from cluster
trials, we would have performed sensitivity analyses to investigate
the robustness of our findings. We had intended to perform a
sensitivity analysis, to consider excluding studies that were at high
risk of bias according to the Cochrane ‘Risk of bias’ tool for RCTs
(Higgins 2011), and serious risk of bias according to ROBINS-I
tool for observational studies (Sterne 2016).
We performed no sensitivity analyses because we identified no
cluster-controlled studies, and because all studies included in the
main effects analysis were at high risk of bias according to the
Cochrane tool or at serious risk of bias according to ROBINS-I.
R E S U L T S
Description of studies
Results of the search
See PRISMA flow diagram Figure 1.
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Figure 1. Flow of studies
11Ribavirin for treating Crimean Congo haemorrhagic fever (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
We identified 1161 records, plus a further three references through
contacting experts in the field. From these we identified 611
unique references after removing duplicates. We considered 372
references to be irrelevant for our review, and we were unable to
obtain the articles for 13 of the references.We considered 226 full-
text articles for inclusion, of which we excluded 203. Two did not
report on CCHF, and two reported on outcomes not included in
our review. Fifty-one studies did not report on ribavirin for treat-
ing CCHF, nine had no comparator arm and 27 were single-case
reports. Fifty were cohort studies with fewer than 10 participants,
27 were narrative reviews and 35 studies were editorial letters or
comments on other studies. Twenty-three studies met our inclu-
sion criteria and are included in the review. No prospectively-reg-
istered ongoing studies met the inclusion criteria.
Included studies
See Characteristics of included studies.
We include 23 studies that tested the use of ribavirin in people
with CCHF, with the outcomes of mortality, length of hospital
stay, and requirement for transfusion.
Main effects analysis
For the main effects analysis we include five studies that were not
at critical risk of bias; one RCT of 136 participants (Koksal 2010)
and four non-randomized studies of 612 participants (Elaldi 2009;
Izadi 2009a; Bodur 2011; Dokuzoguz 2013).
Study design
Of the five studies included in our main effects analysis, one study
was an RCT (Koksal 2010), one was a matched cohort study
(Bodur 2011), one was a cohort with a historical control (Elaldi
2009), one was a mixed prospective and retrospective cohort study
(Dokuzoguz 2013), and one was a retrospective cohort (Izadi
2009a).
The design of the studies included in our primary analysis and how
controls were selected varied. Elaldi 2009 used historical controls
from a period when ribavirin was unavailable. Dokuzoguz 2013
selected controls based on clinical criteria including time from on-
set of symptoms to diagnosis or contraindication to oral ribavirin.
Izadi 2009a compared administration of ribavirin given early in
the disease to late in the disease. Bodur 2011 used a retrospective
design that matched 10 participants who received ribavirin to 40
controls that did not, using various clinical and physiological pa-
rameters.
Setting
Four out of the five studies included in the main effects analysis
were conducted in Turkey, and one was conducted in Iran (Izadi
2009a).
Participants
Most participants described in Dokuzoguz 2013 were adults or
adolescents, with the youngest participant aged 16 years. Izadi
2009a described an age range of 11 to 75, with a median age of
29.2 years. It was not possible to ascertain the exact numbers of
adolescents, as they were not described in the included studies. All
of the studies included in our main effects analysis included con-
firmed cases only, using either Ig enzyme-linked immunosorbent
assay (ELISA) or PCR to verify.
Intervention
Doses of ribavirin differed between studies. Elaldi 2009 described
weight-based prescribing (30 mg/kg initial loading dose; 15 mg/
kg 4 times daily for 4 days; 7.5 mg/kg 3 times daily for 6 days).
Dokuzoguz 2013 and Bodur 2011 described standard doses in
adults (4 g daily for 4 days, followed by 2.4 g daily for 6 days).
Doses were broadly the same and full details are described in the ‘
Characteristics of included studies’ table. All studies in this analysis
administered oral ribavirin.
Comparators
None of the participants in the comparator groups received rib-
avirin for the comparison of ribavirin versus no ribavirin. One
study (Izadi 2009a) was included in the main effects analysis that
offered a comparison of early versus late ribavirin; all those in the
comparator arm received ribavirin after four days.
Length of follow-up
No studies specified a length of follow-up. Instead, they relied
upon discharge from hospital or clinical care as the sole measure
of follow-up time.
Subsidiary descriptive analysis
For the subsidiary descriptive analysis we included 18 studies rated
at critical risk of bias. These studies are frequently cited as evidence
of benefit, so we appraised them against the primary outcome of
mortality.
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Study design
The rationale for ‘Risk of bias’ assessments is set out in Table 1.
They all failed to control for confoundingdue to severity of disease,
time from the onset of symptoms to receiving medical care, or all
of these. This critically affected the reliability of data collected for
these studies. ROBINS-I recommends studies at critical risk of
bias are excluded from the review.
All 18 studies at critical risk of bias were retrospective cohort stud-
ies. One study used a cohort of patients treated before the avail-
ability of ribavirin as a control arm. (Sannikova 2009).
Setting
In those studies included in the descriptive analysis 12 were con-
ducted in Turkey, five were conducted in Iran and one study was
set in Russia and was translated from Russian (Sannikova 2009).
There were a number of studies that reported on populations that
overlapped with each other. Our decisions on overlapping studies
are outlined in Appendix 2.
Participants
In the subsidiary descriptive analysis for the comparison of rib-
avirin versus no ribavirin an additional 1214 participants in 10
studies at critical risk of bias were analysed.
In the subsidiary descriptive analysis for the comparison of early
versus late ribavirin an additional 431 participants in 4 studies
received either early or late ribavirin.
Intervention
For the comparison of ribavirin versus no ribavirin doses were
broadly the same; we give full details in the ‘Characteristics of
included studies’ table. Most studies in this analysis administered
oral ribavirin.
For the comparison of early versus late ribavirin, participants re-
ceived ribavirin according to the study author’s definitions of early
versus late. Studies used different cut-off time points for the defini-
tion of early care with ribavirin, either less than three days since on-
set of symptoms (Sharifi-Mood 2006; Sharifi-Mood 2013a), less
than four days since onset of symptoms (Izadi 2009a) or less than
five days since the onset of symptoms (Metanat 2005; Tasdelen
Fisgin 2009). 114 participants received ribavirin less than three
days from the onset of symptoms, 97 received ribavirin after 3 days
since the onset of symptoms. One hundred and thirty participants
received ribavirin less than five days from onset of symptoms with
90 participants receiving ribavirin after this time point.
Comparators
Of those studies covered by the descriptive analysis, four stud-
ies included children only (Sharifi-Mood 2006; Tuygun 2012;
Gayretli Aydin 2015; Tezer 2016). Three studies did not report
themethod used to confirm cases of CCHF (Metanat 2005; Tulek
2012; Sharifi-Mood 2013a), all other studies used either Ig ELISA
or PCR.
Length of follow-up
No studies specified a length of follow-up. Instead they relied
upon discharge from hospital or clinical care as the sole measure
of follow-up time.
Excluded studies
We excluded 203 studies at the full-text screening stage because
they did not studyCCHF, did not relate to a relevantCCHF topic,
had fewer than 10 participants, or they were narrative reviews or
commentaries. See the Excluded studies tables.
Risk of bias in included studies
Main effects analysis
Randomized controlled trials
We identified one randomised control trial (Koksal 2010), which
we assessed using the Cochrane ‘Risk of bias’ tool for RCTs (
Higgins 2011). Methods for random sequence generation and
allocation concealment were unclear in the single RCT. The trial
authors did not report methods for this in the text. We judged the
methods for blinding of participants and outcome assessments to
be unclear; we identified no missing data.
There was no protocol available to assess selective reporting. We
judged mortality and length of hospital stay as unlikely to be sub-
ject to reporting bias (Figure 2).
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Figure 2. ‘Risk of bias’ assessment for all included trials
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Non-randomized studies
We identified 22 non-randomized studies, whichwe assessed using
the ROBINS-I tool. Of these we classified 18 studies as being at
critical risk of bias, and four studies at serious risk of bias.
Confounding
We have presented comprehensive ‘Risk of bias’ assessments for
non-randomized studies included in the main effects analysis in
Table 2; Table 3; Table 4; Table 5.
One study (Bodur 2011) controlled for confounding by matching
baseline characteristics of 10 cases with 40 controls (Table 2). One
mixed retrospective/prospective cohort study (Dokuzoguz 2013)
established a severity scoring index and stratified results using this
as a way of controlling for confounding by severity. Time from
onset of symptoms to diagnosis was addressed by not prescribing
ribavirin to anyone with more than seven days history of symp-
toms (Table 3). One historically-controlled cohort study (Elaldi
2009) established similar baseline characteristics between cohorts.
The use of a historical control arm at the onset of an epidemic
establishes a difference in the quality of supportive care between
groups. The time period elapsed was only one year, so we classified
this as serious and not critical confounding (Table 4). One retro-
spective cohort study (Izadi 2009a) stratified mortality outcome
by time from onset of symptoms to administration of ribavirin
(Table 5). This study performed a regression analysis, although
this was designed to identify predictive factors for mortality and
not to control for confounding. We classified all four non-ran-
domized studies included in the main effects analysis as being at
serious risk of bias for the domain of confounding.
Bias in selection of participants into the study
In Bodur 2011 (Table 2), participants were matched by their base-
line severity according to clinical presentation and laboratory val-
ues. The trial authors did not adequately describe the matching
process, although stated the controls were selected “at random”.
The lack of clarity meant that we classified this study as being at
serious risk of bias in this domain.
In Dokuzoguz 2013 (Table 3), participants in the control group
were selected based on time from onset of symptoms (more than
seven days) and clinical contraindication. Both are prognostic fac-
tors that predict whether the individual receives the intervention.
We therefore judged this as being at serious risk of bias for this
domain. We did not judge this domain as critical, because baseline
severity was established, measured, and sufficiently comparable to
garner useful data from the study.
In Elaldi 2009 (Table 4), selection of participants was not related
to the intervention, outcome, or any prognostic factor; the his-
torical control group may have confounded results. We therefore
judged this domain to be at serious risk of bias. We did not judge
this domain as critical, because baseline severity was established,
measured, and sufficiently comparable to garner useful data from
the study.
In Izadi 2009a (Table 5), it was unclear if selection into the study
was based on participants’ characteristics observed after the start
of the retrospective study design.
Bias in classification of interventions
We judged all studies to be at low risk of bias, as the doses and
methods of administration of ribavirin were well-defined.
Bias due to deviations from intended interventions
We judged all studies to be at low risk of bias. In none of the studies
were there deviations from the intended intervention other than
what would be expected in normal practice.
Bias due to missing data
In Dokuzoguz 2013 there were some missing outcome data not
described in the text. The missing data were related to numbers
of participants receiving co-administration of corticosteroids with
ribavirin. We judged the balance of missing data across groups as
unclear, as there was insufficient documentation explaining this.
We therefore classed this study as being at serious risk of bias in
this domain.
Bias in measurement of outcomes
We judged all studies to be at low risk of bias. Whilst investigators
will have been aware of the intervention status of the participants
(if they received ribavirin or not), none of the measured outcomes
were subjective and thus prone to bias.
Bias in the selection of reported result
Bodur 2011 and Elaldi 2009 used unclear criteria to establish sim-
ilar baseline characteristics between arms. Most of the expected
clinical and laboratory criteria were included, but a severity score
would be more comprehensive. Whilst severity indices have been
developed since the publication of these papers, an accepted sever-
ity index was available at the time (Swanepoel 1987). We there-
fore classed both studies as being at moderate risk of bias in this
domain.
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Subsidiary descriptive analysis
We classified all 18 studies included in the descriptive analysis as
being at critical risk of bias due to confounding, as described in
Table 1. All of these studies were retrospective cohorts by design.
The main reason for this was the failure to control for baseline
confounding due to severity of disease. Most studies did not de-
scribe important baseline characteristics in intervention and con-
trol groups.
Effects of interventions
See: Summary of findings for the main comparison Ribavirin
versus no ribavirin for Crimean Congo haemorrhagic fever;
Summary of findings 2 Early versus late supportive care plus
ribavirin for Crimean Congo haemorrhagic fever
Our main effects analysis included one RCT and four non-ran-
domized studies. The remaining 18 studies, which we assessed as
being at critical risk of bias, are used in a subsidiary descriptive
analysis for our primary outcome of mortality.
Ribavirin versus no ribavirin
Mortality
One RCT and three non-randomized studies were included that
compared the effect on mortality of ribavirin and no ribavirin in
participants with CCHF (Figure 3).
Figure 3. Forest plot of Ribavirin versus no ribavirin, outcome: mortality.
RCT
One RCT of 136 participants (Koksal 2010) found no statistically
significant effect in favour of either ribavirin or no ribavirin (RR
1.13, 95% CI 0.29 to 4.32; Analysis 1.1).
Non-randomized studies
One mixed retrospective and prospective cohort study of 281 par-
ticipants stratified risk of death by severity of disease (Dokuzoguz
2013). No deaths occurred in 103 mild cases and risk ratios were
therefore not calculable. In 152 moderate cases (subgroup 2) rib-
avirin reduced mortality (RR 0.09, 95% CI 0.02 to 0.50). In 26
severe patients no effect of ribavirin on mortality was seen (RR
0.79, 95% CI 0.44 to 1.41; Analysis 1.2, Figure 4 ). The two
participants in the severe disease strata control group were unable
to take oral ribavirin due to gastro-intestinal bleeding, despite an
intention to treat them with ribavirin.
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Figure 4. Forest plot of comparison: 1 Ribavirin versus no ribavirin, outcome: 1.2 Mortality stratified by
severity of disease (Dokuzoguz 2013).
One cohort study with a historical control arm of 218 partici-
pants had similar baseline characteristics in terms of severity of dis-
ease and time from onset of symptoms (Elaldi 2009). This study
showed no statistically significant benefit of ribavirin on mortality
(RR 0.60, 95% CI 0.26 to 1.38; Analysis 1.1)
One retrospective matched cohort study of 50 participants used a
matched design where those who received ribavirin were randomly
matched to a control group with similar baseline characteristics
(Bodur 2011). In this study no statistically significant effect was
seen (RR 1.33, 95% CI 0.32 to 5.64; Analysis 1.1).
In a pooled analysis of these three non-randomized studies we
found no statistically significant effect (RR 0.72, 95% CI 0.41 to
1.28; 549 participants; Analysis 1.1; Figure 3). With few events
and wide CIs containing clinically appreciable benefit and harm,
it is not possible to draw a conclusion of benefit or of no effect
from the available evidence. Given the concerns over the internal
validity of the studies, this further decreases our confidence in the
effect estimate.
In summary, it is uncertain whether ribavirin reduces mortality,
because the certainty of the evidence is very low from both the
RCT and the non-randomized studies (Summary of findings for
the main comparison).
Length of hospital stay
One non-randomized study (retrospectivematched cohort design)
and one RCT met our inclusion criteria and evaluated the effect
of ribavirin on length of hospital stay in participants with CCHF
receiving ribavirin or not (Koksal 2010; Bodur 2011; Analysis 1.3;
Figure 5).
Figure 5. Forest plot of ribavirin versus no ribavirin, outcome: length of hospital stay (days).
RCT
Koksal 2010 showed no effect of ribavirin on the length of hospital
stay in days (MD 0.70, 95% CI -0.39 to 1.79; 136 participants;
Analysis 1.3).
Non-randomized studies
Bodur 2011 showed no effect of ribavirin on the length of hospital
stay in days (MD -0.80, 95% CI -2.70 to 1.10; 50 participants;
Analysis 1.3).
In summary, we do not know if ribavirin reduces the length of stay
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in hospital, as the certainty of the evidence is very low (Summary
of findings for the main comparison).
Requirement for transfusion
One included RCT compared the effect of ribavirin with no rib-
avirin on the need for transfusion of blood products in partici-
pants with CCHF (Koksal 2010). There was no statistically sig-
nificant difference in requirement for transfusion of platelets be-
tween treated and untreated participants in the RCT (RR 1.23,
95% CI 0.77 to 1.96; 136 participants; Analysis 1.4).
Withdrawal of treatment due to adverse events
One study included in the primary analysis reported on adverse
events leading to discontinuation of treatment. One participant
among 44 who received ribavirin and corticosteroids discontinued
ribavirin due to elevated amylase levels (Dokuzoguz 2013).
Serious adverse events
No studies in the primary analysis reported on adverse events.
Timing of administration of ribavirin: early versus late
ribavirin
Mortality
One non-randomized study (retrospective cohort) was included
that addressed the timing of administration of ribavirin alongside
supportive care and mortality (Izadi 2009a).
Izadi 2009a outlined an association between reduced mortality in
those who received supportive care and ribavirin less than four
days since the onset of any symptoms compared to those receiving
supportive care and ribavirin after four days (RR 0.39, 95% CI
0.16 to 0.95; 63 participants; Analysis 2.1; Figure 6).
Figure 6. Forest plot early versus late ribavirin, outcome: mortality in early versus late ribavirin.
Whilst an association was seen between early supportive care and
ribavirin and reduced mortality in one included study at serious
risk of bias, we are uncertain if early ribavirin is more effective
than late ribavirin in treating CCHF. Separating the effect of early
presentation to hospital, early diagnosis and early supportive care
from the effect of early ribavirin treatment is very difficult without
an adequately-powered randomised study.
Subsidiary descriptive analyses
Ribavirin versus no ribavirin
In the subsidiary descriptive analysis we explored the effect of con-
founding on the effect estimates for ribavirin versus no ribavirin.
We included 10 studies at critical risk of bias that reported mor-
tality outcomes. We established a non-overlapping sample using
the methods described in Appendix 2 and present these in a forest
plot alongside the single RCT and cohort studies at serious risk
of bias (Analysis 3.1; Figure 7). In these studies with a critical
risk of bias, the point estimates shows an effect skewed towards
benefit for ribavirin (1 RCT; RR 1.13, 95% CI 0.29 to 4.32; 136
participants; 3 non-randomized studies at serious risk of bias; RR
0.72, 95% CI 0.42 to 1.28; 549 participants; 10 non-random-
ized studies at critical risk of bias RR 0.43, 95% CI 0.22 to 0.86;
1214 participants). There was also increasing heterogeneity (NRS
serious risk of bias I2 statistic = 0%; NRS critical risk of bias I
2 statistic = 58%). This supports the conclusions of a previous
meta-analysis (Soares-Weiser 2010) that the effect seen is likely
to be attributable to confounding and that no evidence of benefit
could be drawn. Secondly, our descriptive analysis demonstrates
that a critical failure to control for confounding is associated with
an increase in heterogeneity and inconsistency between studies.
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Figure 7. Forest plot of subsidiary descriptive analysis: ribavirin versus no ribavirin, outcome: mortality.
Early versus late supportive care with ribavirin
In the subsidiary descriptive analysis of early versus late ribavirin,
we explored the effect of confounding of the effect estimates. We
included four studies at critical risk of bias and present these in a
forest plot alongside the single non-randomized study at serious
risk of bias (Analysis 4.1; Figure 8).
19Ribavirin for treating Crimean Congo haemorrhagic fever (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Figure 8. Forest plot of comparison: 4 Subsidiary descriptive analysis: early versus late supportive care with
ribavirin, outcome: 4.1 Mortality stratified by study type.
Our subsidiary descriptive analysis showed an association between
early supportive care with ribavirin and a reduction inmortality in
studies with critical risk of bias (4 NRS; RR 0.57, 95% CI 0.38 to
0.85; 431 participants), there was no difference in effect compared
to the study at serious risk of bias (1 NRS; RR 0.39, 95% CI 0.16
to 0.95; 63 participants; I2 statistic = 0%).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Early versus late supportive care plus ribavirin for Crimean Congo haemorrhagic fever
Patient or population: people diagnosed with suspected or conf irmed Crimean Congo haemorrhagic fever
Setting: global
Intervention: early support ive care plus ribavirin1
Comparison: late support ive care plus ribavirin
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with Late ribavirin Risk with Early ribavirin
Mortality in early ver-
sus late support ive care
plus ribavirin
400 per 1000 156 per 1000
(64 to 380)
RR 0.39
(0.16 to 0.95)
63
(1 non-randomised
study)
⊕©©©
VERY LOW2,3
-
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate. The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited. The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate. The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Early def ined according to that reported in the included study (< 4 days since onset of symptoms)
2Downgraded one level for risk of bias: all studies at serious risk of bias.
3Downgraded two levels for imprecision: few events and wide CIs.
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D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison; Summary of
findings 2.
Five studies met the inclusion criteria for our main effects analysis.
These was one RCT with 136 participants and four non-random-
ized studies with 612 participants. We judged all four non-ran-
domized studies to have serious risk of bias by ROBINS-I. There
were a further 18 non-randomized studies classified at critical risk
of biaswhichwe included in a subsidiary descriptive analysis.None
of these studies attempted to control for confounding.
We do not know if ribavirin reduces mortality (very low-certainty
evidence).
We do not know if ribavirin is more effective when given early
with supportive care rather than late with supportive care (very
low-certainty evidence), and we do not know if ribavirin reduces
the length of stay in hospital (very low-certainty evidence).
In terms of possible adverse effects, we do not know if it reduces the
risk of patients needing platelet transfusions (very low-certainty
evidence), and we do not know what the adverse effects of treating
CCHF with ribavirin are, because there is a lack of data for this
outcome.
In the subsidiary descriptive analysis of studies with a critical risk
of bias, the point estimates show an effect skewed towards benefit
for ribavirin, as well as increasing heterogeneity.
Overall completeness and applicability of
evidence
This review includes a single RCT and 22 non-randomized studies
from multiple countries in Europe and Asia. We found no studies
from Africa, where CCHF is also endemic.
There is insufficient reliable evidence to be confident of the effects
of ribavirin on mortality, length of hospital stay or the need for
transfusion of blood products. There is insufficient high-quality
evidence to draw conclusions about the likelihood of serious ad-
verse events occurring when administering ribavirin to people in-
fected with CCHF. Ribavirin is frequently used in the treatment
of hepatitis C and the side-effect profile is well established (Brok
2009). However, given different dosing schedules and the differ-
ences in the length of use of ribavirin, we do not think this evi-
dence is sufficiently generalizable to CCHF.
We wondered whether the non-randomized studies would be suf-
ficient to show a benefit for ribavirin if indeed they had a very large
effect on mortality and were of sufficient quality. However, all but
four of the studies were at critical risk of bias, which means draw-
ing inferences from these studies is not possible (Sterne 2016).
In those non-randomized studies not at critical risk of bias, the
evidence base is not of sufficient robustness to draw conclusions
about benefit or harm, given our concerns about the internal va-
lidity of the studies and imprecision of the effect estimates.
Certainty of the evidence
The overall certainty of the evidence for all outcomes was very
low. Any estimate of effect is highly uncertain and is likely to
change with further research on the treatment of CCHF. Most
research done in this area is of non-randomized designs and is crit-
ically compromised by uncontrolled confounding and small sam-
ple sizes. Because of this, we are unable to reach any conclusions
on the efficacy of ribavirin for treating CCHF.
For mortality, the single RCT, which was the study with the most
reliable internal validity and which we felt provided the most reli-
able effect estimate, was at high risk of bias and underpowered to
show an effect, with few events. As a result we downgraded it to
very low-certainty evidence for the outcome of mortality.
For mortality in early versus late ribavirin, all studies were of a
non-randomized design at serious risk of bias. The pooled effect
estimate included few events and broad CIs, which meant we
downgraded the evidence to very low certainty.
For length of hospital stay, the single RCT was at high risk of bias
and underpowered to show an effect, with few events.We therefore
downgraded it to very low-certainty evidence for this outcome.
For the requirement for transfusion of blood products, the single
RCT was at high risk of bias and underpowered to show an effect,
with few events. We therefore downgraded it to very low certainty
evidence for this outcome.
Potential biases in the review process
We have minimized the effect of confounding bias on the effect
estimates in the non-randomized studies by only presenting those
at serious, moderate, high, low or unclear risk of bias in the main
analysis. To describe the effect of confounding we conducted a
subsidiary analysis only including those studies at critical risk of
bias. We used the latest tools in assessing risk of bias in non-ran-
domized studies. We sought guidance from specialist methodolo-
gists developing the ROBINS-I tool to aid our processes. Despite
these efforts, we included no studies in this review with a low risk
of bias, which means that confounding is still likely to bias any
estimates in the main effects analysis.
The included studies populations largely came from Turkey and
Iran, with little evidence available from other countries, although
we attempted to include a broad range of geographic locations by
searching extensively for literature and by including a PhD thesis
from Russia (Sannikova 2009).
Agreements and disagreements with other
studies or reviews
A previous systematic review (Soares-Weiser 2010) concluded that
there was no clear evidence of benefit from the data then avail-
able, as non-randomized studies were heavily confounded. In our
review we have tried to stratify analysis by different degrees of
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confounding in the studies. This analysis agrees with the opinion
of the authors of the Soares-Weiser review that the effect seen in
their meta-analysis was likely to have been due to confounding in
non-randomized studies.
Soares-Weiser 2010 included two further studies not included in
our review. We excluded these studies because of a sample size of
less than 10 participants (Jamil 2005), and the lack of a comparator
arm (Nadeem 2003). See the Excluded studies section.
We agree with the assessment of the authors of the Ascioglu 2011
review about the internal validity of the included studies and the
effect of systematic bias on the effect estimate. We further agree
that the results of a meta-analysis of flawed studies cannot be used
as evidence of an effect, and that a randomised controlled trial is
needed and ethically justified, given the ambiguity of observational
studies.
All studies included in the Ascioglu 2011 systematic review are
included in our review.
We agree with the two previous systematic reviews on this topic
(Soares-Weiser 2010; Ascioglu 2011). We cannot draw conclu-
sions about the efficacy of ribavirin for treating Crimean Congo
haemorrhagic fever using the data currently available. This is
largely attributable to too few studies that adequately control for
confounding and the lack of a reliable RCT. Any estimate of effect
based on currently available data is very uncertain.
Research in outbreaks
In a broader sense, the current status of the evidence for ribavirin
in CCHF highlights the difficulties when non-randomized studies
or consensus is used to establish a treatment in the absence of
reliable evidence. Once established as standard practice, clinicians
feel uneasy about the ethics of conducting a placebo controlled
trial whether reliable evidence of efficacy exists or not. This is
made more acute because of a previous lack of preparedness for
experimental research therapeutics in outbreak situations. In 2016
WHO issued guidance on managing ethical issues in infectious
disease outbreaks which highlights the need to learn as much as
possible as quickly as possible and that in such situations where
no proven treatment exists research should be conducted using
rigorous methodology that is capable of providing valid results
(WHO 2016).
Whilst monitored use of experimental or unproven therapies can
be ethically justifiable in outbreak situations provided; 1) no
proven effective treatment exists; 2) it is not possible to initiate
clinical studies immediately; 3) data providing preliminary sup-
port of the intervention’s efficacy and safety are available; 4) the
relevant country authorities, as well as an appropriately qualified
ethics committee, have approved such use; 5) adequate resources
are available to ensure that risks can be minimized; 6) the pa-
tient’s informed consent is obtained; and 7) the emergency use of
the intervention is monitored and the results are documented and
shared in a timely manner with the wider medical and scientific
community (WHO 2016). It is important always to be clear that
no harm is likely, considering the potential for causing harm is
important as sometimes there is a perception that any interven-
tion will help because of the high mortality, however, a harmful
intervention could push case fatality rates even higher as well as
potentially costing valuable time and resources.
As this review demonstrates, establishing efficacy of a therapeutic
in acute infectious diseases using observational or non-randomised
data is difficult and results can be unreliable. As such the ability to
conduct methodologically rigorous research that is able to demon-
strate efficacy should be a requirement of any use of unproven
therapeutics in outbreak situations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We do not know from the current literature if ribavirin is an ef-
fective treatment for CCHF. Most research on this question is of
a non-randomized design and is critically confounded. Any esti-
mates of effect based on the existing literature is highly uncertain
and likely to change with further methodologically rigorous re-
search.
Implications for research
This review improves on the previous systematic reviews by in-
cluding all the relevant information from observational studies
and assessing them systematically. We have used the latest meth-
ods examining confounding and other important methodologi-
cal aspects important in assessing the findings of non randomised
studies looking at the effects of ribavirin in CCHF.
There remains considerable controversy on the effects of ribavirin
in CCHF and whether to use it, reflecting true uncertainty in the
field, with some strong advocates (Ergonul 2006); and others rec-
ommend supportive care only (Kalin 2014). These clear variations
in practice and viewpoints and the lack of any clear message from
this independent systematic review of the of the evidence point
us in the direction of a randomised clinical trial to establish or
disprove the efficacy of ribavirin, as has been suggested previously
(Soares-Weiser 2010; Ascioglu 2011).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alavi-Nani 2006
Methods Retrospective cohort study
Participants 255/155 confirmed cases
Age NR, Gender 22.4% female
Interventions Ribavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x
daily for 6 days oral
Outcomes Mortality
Location and dates Boo-Ali Hospital, Zahedan + Zabol: Sistan-Baloochestan province, Iran
Unclear - whether patients treated at hospital that is source of study June 1999 - February
2004
Number of days since onset of symptoms
(mean/SD)
Mean incubation period 4.4 days (SD = 2.6, range 1 - 14) (whole study population)
Supportive therapy NR
Notes
Belet 2014
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Location and dates University Faculty of Medicine, Samsun, Turkey; Tertiary care centre CCHF reference
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(mean/SD)
Mean: 3.6 (SD = 2.4) (range = 1 - 15)
Supportive therapy FFP, thrombocyte suspension or erythrocyte suspension
Notes Children
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Bodur 2011
Methods Matched retrospective cohort study
Participants 50 confirmed cases
Interventions Ribavirin 4 g/day for 4 days and then 2.4 g/day for 6 days oral
Outcomes Mortality, length of hospitalisation, requirement for transfusion (PRC), requirement for
transfusion (FFP), requirement for transfusion (platelets) - RBV versus no RBV
Location and dates Ankara Numune Education and Research Hospital, Ankara, Turkey 2006 - 2008
Number of days since onset of symptoms
(mean/SD)
Ribavirin 4.3 ± 1.4 (to hospitalisation); Control group 4.4 ± 1.4 (to hospitalisation)
Supportive therapy Erythrocytes, platelets, FFP, or hydration according to homeostatic status
Notes
Cevik 2008
Methods Case-control study
Participants 25 confirmed cases
Age NR, Sex NR
Interventions Ribavirin loading dosage of 17 mg/kg IV, then 17 mg/kg every 6 h for 4 days, and then
8 mg/kg every 8 h for 6 days
Intravenous administration
Outcomes Mortality, SAEs, length of hospitalisation, treatment discontinuation, requirement for
transfusion (PRC, FFP, platelets)
Location and dates Ankara Numune Education and Research Hospital and Sivas Cumhuriyet University
Hospital, Ankara, Turkey May - August 2006
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy NR
Notes
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Dokuzoguz 2013
Methods Prospective and retrospective cohort study
Participants 281 confirmed cases,
mean age 47 (SD = 16) (range = 16 - 86), 49% women
Interventions Ribavirin with or without corticosteroids,
Ribavirin: 4 g daily for 4 days, followed by 2.4 g daily for 6 days; Corticosteroids: 10
mg/m2 dexamethasone; oral ribavirin, corticosteroids route NR. Unclear proportions of
patients received steroids
Outcomes Severity scoring index, mortality
Location and dates Ankara Numune Education and Research Hospital, Ankara, Turkey tertiary centre 2004
- 2011
Number of days since onset of symptoms
(mean/SD)
All patients < 7 days
Supportive therapy Erythrocytes, platelets,and total blood according to homeostasis needs
Notes
Elaldi 2009
Methods Historical control study
Participants 218 confirmed cases,
Mean age: ribavirin group mean 44.4 (SD = 19.1); No-ribavirin group mean 40.9 (SD
= 16.7), 50% women
Interventions Ribavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x
daily for 6 days; Oral (nasogastric tube if oral not possible)
Outcomes Mortality, length of hospital stay, requirement for transfusion (PRC, FFP, platelets)
Location and dates Cumhuriyet University; Ankara Numune Training Hospital, Ataturk University Re-
search Hospital; Ondokuz Mayis University, Sivas; Ankara; Erzurum; Samsun, Turkey
tertiary centres 2004
Number of days since onset of symptoms
(mean/SD)
Median 5 (range = 1 - 11)
Supportive therapy Erythrocyte suspensions,platelet suspensions, FFP and other supportive as required
Notes
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Ergonul 2006
Methods Retrospective cohort study
Participants 54 confirmed cases
Interventions Ribavirin 4 g 4 x daily for 4 days, and 2.4 g 4 x daily for 6 days; oral
Outcomes Mortality
Location and dates Ankara Numune Education and Research Hospital, Ankara, Turkey tertiary centre 2002
- 2004
Number of days since onset of symptoms
(mean/SD)
5.5
Supportive therapy Erythrocytes, platelets, and total blood according to homeostasis needs
Notes
Ergönül 2004
Methods Prospective cohort study
Participants 35 confirmed cases
Mean age 43 (SD = 17), 51% women
Interventions Ribavirin 4 g 4 x daily for 4 days, and 2.4 g 4 x daily for 6 days; oral
Outcomes Mortality (severe CCHF cases only)
Location and dates Ankara Numune Education and Research Hospital, Ankara, Turkey tertiary centre 2002
- 2003
Number of days since onset of symptoms
(mean/SD)
5.5 (SD = 1.7)
Supportive therapy Erythrocytes, platelets, and total blood according to homeostasis needs
Notes
Ertem 2016
Methods Retrospective cohort study
Participants 56 confirmed cases
Interventions Ribavirin 2 g as an initial loading dose, then 1 g 4 x daily for 4 days, and then 0.5 g 4 x
daily for 6 days
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Ertem 2016 (Continued)
Oral ribavirin
Outcomes Mortality, length of hospitalisation, requirement for transfusion (FFP), requirement for
transfusion (platelets), SAEs
Location and dates Ankara Training and Research Hospital in Central Anatolia, Ankara, Turkey tertiary
centre 2007 - 2010
Number of days since onset of symptoms
(mean/SD)
Early ribavirin, median 2 (range = 1 - 5 days); Late ribavirin, median 5 (range = 4 - 8
days); No ribavirin, median 3 (range 1 - 10 days)
Supportive therapy Erythrocytes, platelets, FFP, or hydration as needed
Notes Comparator - late ribavirin
Ertugrul 2009
Methods Retrospective cohort study
Participants 61 cases, 26 confirmed
Interventions Ribavirin - route and dose NR
Outcomes Mortality
Location and dates Adnan Menderes, University Medical Faculty, Aydin, Turkey, Hospital/community:18/
26 cases admitted to hospitals April 2007 - Jun 2008
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy NR
Notes
Gayretli Aydin 2015
Methods Retrospective cohort study
Participants 26 confirmed cases
Age 10 years ± 2, sex 30.7% female
Interventions Ribavirin 30 mg/kg as an initial loading dose, followed by 15 mg/kg every 6 h for 4 days,
and then 7.5 mg/kg every 8 h for 6 days; oral
Outcomes Mortality
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Gayretli Aydin 2015 (Continued)
Location and dates Maternity and Children’s Research and Education Hospital, Ankara, Turkey, tertiary
hospital 2005 - 2013
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy Replacement of fluid and electrolytes, and administration of platelet suspension, FFP
and erythrocyte suspension
Notes Study only included children
Izadi 2009a
Methods Retrospective cohort study
Participants 63 confirmed cases
Mean age 29.2 years (range = 11 - 75 years), sex NR
Interventions Early ribavirin (< 4 days), late ribavirin (> 4 days)
For adults, 2 g of ribavirin had been prescribed initially as a loading dose, followed by 1
g every 6 h for 4 days and then 500 mg every 8 h for 6 days
For children, a 30 mg/kg bolus was initially administered, followed by 15 mg/kg every
6 h for 4 days; oral
Outcomes Mortality
Location and dates Boo-Ali Educational Hospital, Zahedan, Iran, tertiary centre, 2000 - 2006
Number of days since onset of symptoms
(mean/SD)
Mean 5.0 (SD = 1.6)
Supportive therapy Blood products
Notes
Kalin 2014
Methods Retrospective cohort study
Participants 81 confirmed cases
Mean age: ribavirin group 54 ± 14.98; no-ribavirin group 42.81 ± 16.50
Interventions Ribavirin 2 g loading then 4 g/day maintenance; oral ribavirin
Outcomes Mortality, requirement for transfusion (FFP, PRC, platelets)
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Kalin 2014 (Continued)
Location and dates Erciyes University Hospital and Yozgat State Hospital, Kayseri and Yozgat, Turkey, ter-
tiary centre. January 2007 - December 2010
Number of days since onset of symptoms
(mean/SD)
Ribavirin: median = 5 days, No ribavirin: median = 7 days
Supportive therapy Erythrocytes, platelets, FFP, or hydration according to homeostatic status
Notes Severity assessed according to Swanepoel and Ergonul criteria
Koksal 2010
Methods RCT
Participants 136 confirmed cases
Mean age 49.2
Interventions Ribavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x
daily for 6 days; Oral ribavirin
Outcomes Mortality, length of hospital stay, requirement for transfusion
Location and dates Karadeniz Hospital, Trabzon, Turkey, tertiary centre; June 2004 - August 2007
Number of days since onset of symptoms
(mean/SD)
Ribavirin: mean 4.5 (SD = 2.5); No ribavirin: mean 3.9 (SD = 2.4)
Supportive therapy Supportive care and fluid, platelet, FFP, blood products as necessary
Notes
Mardani 2003
Methods Retrospective cohort study
Participants 139 suspected, 69 confirmed cases
Age: 68.9% < 33 years of age
Interventions Ribavirin 30 mg/kg initial loading dose; 15 mg/kg 4 x daily for 4 days; 7.5 mg/kg 3 x
daily for 6 days; Oral (nasogastric tube of oral not possible)
Outcomes Mortality
Location and dates Shahid Beheshti University and regional hospitals, Tehran and regions: Sistan Balouch-
estan, Esfahan, Golestan, Iran Patients treated at “local hospitals where they had pre-
sented”; June 1999 - September 2001
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Mardani 2003 (Continued)
Number of days since onset of symptoms
(mean/SD)
Mean 4 days
Supportive therapy NR
Notes
Metanat 2005
Methods Retrospective cohort study
Participants 179 cases
Age; NR
Interventions Oral ribavirin, dose NR; early intervention < 5 days since onset of symptoms
Outcomes Mortality
Location and dates Boo-Ali Hospital in Zahedan, Zahedan, Iran tertiary centre; Dates NR
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy NR
Notes Conference abstract
Ozkurt 2006
Methods Retrospective cohort study
Participants 60 confirmed cases
Mean age: 40 ± 17 (range = 15 - 76) years
Interventions Ribavirin 2000 mg orally initial loading dose, then 1000 mg every 6 h for 4 days, and
then 500 mg every 6 h for 6 days;
Oral
Outcomes Mortality, duration of hospitalisation, SAEs, requirement for transfusion (PRC), require-
ment for transfusion (FFP), requirement for transfusion (platelets)
Location and dates Ataturk University Research Hospital, Eastern Turkey, Turkey tertiary centre 2002 -
2004
Number of days since onset of symptoms
(mean/SD)
Ribavirin group 6 (SD = 2.27); No-ribavirin group 6.5 (SD = 3.46)
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Ozkurt 2006 (Continued)
Supportive therapy Fluid, platelet, blood, or components were replaced if necessary
Notes
Sannikova 2009
Methods Retrospective cohort study [PhD thesis]
Participants 404 confirmed cases
Interventions Ribavirin: 1200 mg if > 75 kg, 1000 mg if < 75 kg
Outcomes Mortality
Location and dates Stavropol’ State Medical Academy, Russia 1999-2008
Number of days since onset of symptoms
(mean/SD)
Early ribavirin 1 - 3 days; Late ribavirin 2 - 6 days
Supportive therapy Blood products and fluids as indicated
Notes
Sharifi-Mood 2006
Methods Retrospective cohort study
Participants 29 confirmed cases
Age 5 - 17 years
Interventions Early ribavirin (< 3 days) 30 mg/kg as an initial dose, then 15 mg/kg every 6 h for 4
days, then 7.5 mg/kg every 8 h for 6 days; Late ribavirin (> 3 days); Oral ribavirin
Outcomes Mortality
Location and dates Departments of Infectious Diseases, Boo-Ali Hospital and Iman-Ali Hospital in Zabol,
Province: Sistan and Baluchistan (south-east Iran), Province: Sistan and Baluchistan
(south-east Iran) tertiary centre June 1999 to February 2006
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy NR
Notes Study conducted only in children
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Sharifi-Mood 2013a
Methods Retrospective cohort study
Participants 184 cases,
Age NR
Interventions Early ribavirin (< 3 days) 30 mg/kg of body weight as an initial dose and then 15 mg/kg
every 6 h for 4 days, and thereafter 7.5 mg/kg for 6 days; Oral
Comparator: Late ribavirin (> 3 days) Same regimen as early ribavirin; Oral
Outcomes Mortality
Location and dates Boo-Ali Hospital, Sistan and Baluchestan, in Southeast of Iran, Iran tertiary centre
January 2000 - September 2005
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy NR
Notes
Tasdelen Fisgin 2009
Methods Retrospective cohort study
Participants 52 cases (unknown if confirmed)
Interventions Ribavirin versus no ribavirin; dose and route not recorded
Outcomes Mortality, requirement for transfusion (platelets)
Location and dates Ondokuz Mayis University Faculty of Medicine, Samsun, Turkey tertiary centre 2004 -
2007
Number of days since onset of symptoms
(mean/SD)
Early ribavirin 1 - 4 days, late ribavirin 5 or more days
Supportive therapy
Notes
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Tezer 2016
Methods Retrospective cohort study
Participants 46 confirmed cases
Mean age: ribavirin 11.6; no ribavirin 7.3
Interventions Ribavirin, route and dose NR
Outcomes Mortality, length of hospital stay, requirement for transfusion
Location and dates Ankara Hematology Oncology Children’s Training and Research Hospital, Ankara,
Turkey tertiary centre
January 2009 - Novenber 2014
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy Erythrocytes, FFP
Notes Children only
Tulek 2012
Methods Retrospective cohort study
Participants 243 cases (unclear if suspected or confirmed)
Average age NR
Interventions Ribavirin, route and dose NR
Outcomes Mortality
Location and dates Ankara Hospital, Ankara, Turkey tertiary centre, 2007 - 2011
Number of days since onset of symptoms
(mean/SD)
NR
Supportive therapy Similar supportive care in 2 departments involved in study - no further information
provided
Notes
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Tuygun 2012
Methods Retrospective cohort study
Participants 50 confirmed cases
Interventions Oral ribavirin 30 mg/kg as an initial loading dose, then 15 mg/kg every 6 h for 4 days,
and then 7.5 mg/kg every 8 h for 6 days
Outcomes Mortality
Location and dates Dr Sami Ulus Maternity and Children’s Health and Diseases Training and Research
Hospital in Ankara, Turkey; tertiary centre 2005 - 2010
Number of days since onset of symptoms
(mean/SD)
3.5 ± 2.1 (range = 1.0 to 9.0)
Supportive therapy Erythrocyte/thrombocyte suspension, FFP based on homeostatic status and other sup-
portive care
Notes
Abbreviations: FFP = fresh frozen plasma; h = hours; NR: not reported; PRC: packed red cells; RBV: ribavirin; SAE: serious adverse
event; SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abuova 2012 This was a case series with fewer than 10 participants
Ajazaj 2013 This was a case series with fewer than 10 participants
Alavi-Naini 2004 This is a single case report
Ali 2010 This was a case series with fewer than 10 participants
Anon 1984 This was a survey and therefore was a different study design from our inclusion criteria
Ardalan 2006 This was a single case report
Athar 2003 This was a case series with fewer than 10 participants
Athar 2005 This was a case series with fewer than 10 participants
Barr 2013 This was a single case report
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(Continued)
Canpolat 2011 This was a single case report
Caylan 2010 This was a single case report
Ceri 2013 This was a single case report
Chinikar 2013 This was a case series with fewer than 10 participants
Dilber 2010 This was a case series with fewer than 10 participants.
Drosten 2002 This was a single case report and discussion
El Bahnasawy 2015 This was a survey and therefore did not meet inclusion criteria; it was based on a different study design
Elata 2011 This was a case report of a single nosocomial transmission.
Ergonul 2009 This was a commentary on an included study
Ergonul 2014 This was a case series with fewer than 10 participants.
Ergonul 2017 This study compared individuals with CCHF to healthy individuals
Fazlalipour 2016 This was a case series with fewer than 10 participants.
Gonen 2014 This was a case series with fewer than 10 cases
Gozel 2013 This was a case series with fewer than 10 cases
Guner 2014 This was a case series with fewer than 10 participants
Gursoy 2014 Translated from Turkish. This was an editorial letter that reported a single case
Hasan 2013 This was a single case report
Izadi 2009b This is an editorial letter written as a reply to comments on an included study
Jabbari 2006 This was a case series with fewer than 10 participants
Jamil 2005 This was a case series with fewer than 10 participants.
Joubert 1985 This was a case series with fewer than 10 participants.
Kadanali 2012 This was a cohort study that did not compare ribavirin to supportive care only - no comparator arm
Kader 2011 This was a cohort study that did not compare ribavirin to supportive care only - no comparator arm
Kleib 2016 This was a single case report
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(Continued)
Kubar 2011 This reported the effects of administration of hyperimmunoglobulin, not ribavirin
Kunchev 2008 This was a case series with fewer than 10 participants.
Leblebicioglu 2016a This reported on the use of ribavirin for prophylaxis but did not report on ribavirin used as treatment for
disease
Makwana 2015 This was a single case report
Mardani 2009 This was case series of fewer than 10 participants
Mardani 2013 This was a case series with fewer than 10 participants
Midilli 2007 This was a cohort study that did not compare ribavirin to supportive care only - no comparator arm
Mishra 2011 This was a single case report
MMWR 1984 This was a case series with fewer than 10 participants
Mohamed 2016 This was a single case report
Nabeth 2004 This was a single case report
Naderi 2011 This was a case series with fewer than 10 participants.
Naderi 2013 This was a case series with fewer than 10 participants.
NCT00992693 This ongoing study did not include a comparator group where no ribavirin is given
Oflaz 2013 This was a cohort study that did not compare ribavirin to supportive care only - no comparator arm
Ozbey 2014 This did not compare use of ribavirin to supportive care only. It did not report mortality as an outcome
in a useable way, reporting only a case fatality ratio in those who were transferred to tertiary centres or not
transferred. As such this study did not meet our inclusion criteria
Ozsoy 2015 This was a case series with fewer than 10 participants
Papa 2008 This was a single case report
Pourahmad 2011 This was a single case report
Pshenichnaya 2015 This was a case series with fewer than 10 participants
Raoofi 2012 This was a case series with fewer than 10 participants
Richards 2015 This was a case series with fewer than 10 participants
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(Continued)
Sahin 2016 This was a single case report
Saluzzo 1985b This was a single case report
Schwarz 1995 This was a single case report
Scrimgeour 1996 This was a case series with fewer than 10 participants
Sefikotullari 2013 This case series reported different outcomes from those in our review
Sharifi-Mood 2008 This was a cohort study that did not compare ribavirin to supportive care only - no comparator arm
Sharifi-Mood 2009 This was an overlapping study reporting the same data as an included study (Sharifi-Mood 2006)
Sharifi-Mood 2013b This was a quasi-RCT that did not report on ribavirin compared to supportive care only - all participants
received ribavirin with or without corticosteroids
Sheikh 2005 This was a cohort study that did not compare ribavirin to supportive care only - no comparator arm
Sheikh, 2004 This was a case series with fewer than 10 participants
Smego 2004 This was a case series with fewer than 10 participants
Suleiman 1980 This was a case series with fewer than 10 participants
Sunbul 2016 This was a single case report
Tall 2009a This was a single case report
Tall 2009b This was a case series with fewer than 10 participants
Tatar 2005 This was a case series with fewer than 10 participants
Tezer 2014 This was a case series with fewer than 10 participants.
Tulek 2010 This was a case series with fewer than 10 participants
Tutuncu 2009 This was a case series with fewer than 10 participants
Ugurlu 2013 This was a single case report
Unlusoy 2014 This was a single case report
Uysal 2012 This was a single case report
Van Eeden 1985a This was a case series with fewer than 10 participants
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(Continued)
Van Eeden 1985b This was a case series with fewer than 10 participants
Weber 2001 This was a case series with fewer than 10 participants
Yadav 2013 This did not report on ribavirin use in CCHF
Yadav 2016 This did not report on ribavirin use in CCHF
Yesilyurt 2011 This did not report on ribavirin use in CCHF
Yildirmak 2016 This was a case series with fewer than 10 participants
Yilmaz 2009a This did not report on ribavirin use in CCHF
Yilmaz 2009b This was a case series with fewer than 10 participants
Yolcu 2014 This was a survey that did not report on ribavirin use for treatment of CCHF
Zakhashvili 2010 This was a single case report
Öztürk 2012 This was a case series with fewer than 10 participants
RCT: randomized controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Ribavirin versus no ribavirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 RCT 1 136 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.29, 4.32]
1.2 Non-randomized studies 3 549 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.41, 1.28]
2 Mortality stratified by severity of
disease (Dokuzoguz 2013)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Length of hospital stay (days) 2 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 RCT 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Non-randomized studies 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Requirement for transfusion
(platelets)
1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 2. Early versus late supportive care with ribavirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 3. Subsidiary descriptive analysis - Ribavirin versus no ribavirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality stratified study type 14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 RCT 1 136 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.29, 4.32]
1.2 Non-randomized studies
(serious risk of bias)
3 549 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.41, 1.28]
1.3 Non-randomized studies
(critical risk of bias)
10 1214 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.22, 0.86]
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Comparison 4. Subsidiary descriptive analysis: early versus late supportive care with ribavirin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality stratified by study type 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Serious risk of bias 1 63 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.16, 0.95]
1.2 Critical risk of bias 4 431 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.38, 0.85]
A D D I T I O N A L T A B L E S
Table 1. Table of studies at critical risk of bias: disease-related outcomes
Studies at critical risk of bias outcomes: Death, timing of administration, length of stay in hospital, requirement for transfusion
Study Bias due to Confounding Comment
Alavi-Nani 2006 Critical Confounders not controlled for. No information reported
on care received in hospital. Variation in disease severity
between ribavirin and control groups not measured. No
discussion of potential confounding by severity of disease
in paper. No control for time from onset of symptoms
to administration of ribavirin. Small size of control group
suggests clinical contraindication to ribavirin, a factor in
selection into control group (although this is not expressly
commented on)
Belet 2014 Critical Confounders not controlled for. Although criteria for ad-
ministration of ribavirin reported, it is not clear whether
recipients must fulfil all of these or only some
Participants receiving ribavirin were more severe at base-
line. There is no adjustment for severity on admission, and
length of time between symptom onset and admission/
ribavirin treatment
Cevik 2008 Critical Confounders not controlled for. Severe patients only in-
cluded in case-control study. No discussion of potential
confounding in paper. Care provided during hospitalisa-
tion not described
Ergönül 2004 Critical Confounders not controlled for. Severe patients only in-
cluded in retrospective cohort. Baseline severity of disease
not established. Classification of severe disease is at any
time point for 22 participants. Time from onset of symp-
toms not controlled for. No method for dealing with po-
tential confounders. Patients were given preparations of
erythrocytes, fresh frozenplasma, and total blood, depend-
ing on their homeostatic state - disentangling the effect of
this supportive care from that of ribavirin is not consid-
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Table 1. Table of studies at critical risk of bias: disease-related outcomes (Continued)
ered. Oral ribavirin was given to severe CCHF patients
Ergonul 2006 Critical Confounders not controlled for. Paper focuses on devel-
oping severity scoring system. Baseline characteristics not
established between ribavirin and non-ribavirin groups.
Criteria for selection into control arm included clinical
contraindication due to haematemesis. Time from onset
of symptoms not controlled for. The authors developed
specific criteria to identify severe cases
Ertugrul 2009 Critical Confounders not controlled for. No methods for control-
ling potential confounders are discussed. Authors stated in
Discussion that no information was available to them on
severity of cases. No information reported on care received
by participants
Ertem 2016 Critical Confounders not controlled for. Controls for “time from
onset of symptoms” for a comparison of early versus late
ribavirin. However, not for the comparison of ribavirin
versus no ribavirin. Rather than just comparingmeans, the
authors should control for the confounders when compar-
ing the groups. Mortality not reported
Gayretli Aydin 2015 Critical Confounders not controlled for. Paper focuses on brady-
cardia in paediatric patients
No discussion of potential confounding in paper and no
controlling for confounding factors such as severity of ill-
ness or time from onset of symptoms to administration of
ribavirin
Kalin 2014 Critical Confounders not controlled for. Significant differences in
baseline severity of disease and time from onset of symp-
toms. These confounders were measured but not con-
trolled for by stratification or other method. Ribavirin
group hadmore severe disease; confounding would reduce
effect of ribavirin seen
Mardani 2003 Critical Confounders not controlled for. Baseline characteristics
not established between ribavirin and no-ribavirin groups.
No method for dealing with potential confounders. Sig-
nificant differences in arms of study - suggests heteroge-
neous samples with no controlling for severity of disease.
Time from disease onset to presentation/treatment not as-
sessed. Historical control arm used supportive treatment
likely to have differed substantially between intervention
and control arms
Metanat 2005 Critical Confounders not controlled for. Conference abstract - in-
sufficient information reported by study authors about
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Table 1. Table of studies at critical risk of bias: disease-related outcomes (Continued)
possible confounders such as severity of disease. No infor-
mation provided on care received in hospital
Ozkurt 2006 Critical Confounders not controlled for. No methods for control-
ling potential confounders are discussed. Timing of ad-
ministration of ribavirin is documented but severity of in-
fection is not considered. Baseline characteristics not es-
tablished between ribavirin and no-ribavirin groups
Sannikova 2009 Critical Historical control group used. Study conducted from
1999-2008, quality of supportive care likely to have
changed significantly over this period of time. Control
group originated during period before ribavirin was avail-
able. Substantial period of time from the start of follow
up in historical control group to start of follow up in in-
tervention group
Sharifi-Mood 2006 Critical Confounders not controlled for. No information reported
on care received in hospital. Baseline characteristics not es-
tablished. Variation in disease severity expected, although
influence of this across the two groups unclear. Nomethod
of controlling for confounding by severity of disease. No
discussion of potential confounding in paper. Timing of
administration investigated, raw data not presented
Sharifi-Mood 2013a Critical Confounders not controlled for. Time fromonset of symp-
toms adjusted for by stratification into early/late ribavirin.
Baseline characteristics and severity of disease not assessed,
measured or controlled for. No information provided on
care received in hospital
Tasdelen Fisgin 2009 Critical Timing of administration of ribavirin controlled for by
stratification. Baseline confounding due to severity of dis-
ease measured and not controlled for participants in no-
ribavirin group and late-ribavirin group having more se-
vere disease based on baseline biochemistry and haematol-
ogy. At least one participant was included in no-ribavirin
group due to gastrointestinal haemorrhage and severe dis-
ease. Criteria for use of ribavirin changed during period
and largely historical controls were used
Tezer 2016 Critical Confounders not controlled for. No methods for control-
ling potential confounders such as severity of disease and
time since onset of symptoms are discussed. Authors rec-
ognize highly-confounded data as limitation of their study
Tulek 2012 Critical Confounders not controlled for. Case-control study with
no information in abstract about how the controls were
selected. Supportive care protocol was similar in both de-
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Table 1. Table of studies at critical risk of bias: disease-related outcomes (Continued)
partments. No method for dealing with potential con-
founding by time since onset of symptoms. No matching
for severity or time since onset of symptoms
Tuygun 2012 Critical Confounders not controlled for. No method for deal-
ing with potential confounding by time since onset of
symptoms, baseline characteristics were not established,
no method for controlling for severity. The patients were
given erythrocyte suspension, thrombocyte suspension
and/or fresh frozen plasma based on their haemostasis sta-
tus, and other supportive care when necessary - disentan-
gling the effect of this care from that of ribavirin is not
considered. Oral ribavirin was given to the patients who
were evaluated as severe or had bleeding symptoms, or
both
Entirely unclear how the authors selected the 50 partici-
pants included from 202 confirmed cases. Also at critical
risk of bias on selection of participants into the study
Table 2. ROBINS-I assessment: Bodur 2011
ROBINS-I assessment
Reference: Bodur 2011
Risk of bias domain Assessments by outcome Comment Conclusion
Bias due to confounding Mortality, Length of hospital
stay, transfusion, withdrawal of
treatment: serious risk of bias
due to baseline confounding
Matching controls were in-
cluded in the study in order to
increase the study’s power. Base-
line characteristics established
and are similar between groups
for severity of disease and time
from onset of symptoms to ad-
mission
No sig-
nificant differences in baseline
laboratory findings.Differences
occur between groups in rates
of splenomegaly (1 case in each
arm), petechiae, haematemesis
(2/10 in ribavirin group, 3/
40 in control), melena. How-
ever, limited information re-
ported on how the controls or
baseline characteristics were se-
lected.Given the differences in
Serious
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Table 2. ROBINS-I assessment: Bodur 2011 (Continued)
clinical symptoms serious risk
of bias was attributed
Bias in selection of partici-
pants into the study
Mortality, length of hospital
stay, transfusion, withdrawal of
treatment: serious risk of bias
Direction: would show in-
creased effect of ribavirin
Selection into study did not ap-
pear to be related to interven-
tion, outcome or any prognos-
tic factor
Limited information reported
on how the controls were se-
lected
Controls selected “at random”
that matched baseline charac-
teristics
Moderate
Bias in classification of inter-
ventions
All outcomes Interventions well defined Low
Bias due to deviations from
intended interventions
All outcomes No information on deviation
from intended intervention, as
would be the case in usual prac-
tice
Low
Bias due to missing data All outcomes: serious All data appear to be reported Low
Bias in selection of the re-
ported result
All outcomes No outcomes of interest to
study authors are specified. No
protocol available, no prespeci-
fied outcomes in Methods sec-
tion
Serious
Table 3. ROBINS-I assessment Dokuzoguz 2013
ROBINS-I assessment
Reference: Dokuzoguz 2013
Domain Assessments by outcome Comment Conclusion
Bias due to confounding Mortality, length of hospital
stay, transfusion, withdrawal of
treatment: Serious risk of bias
due to baseline confounding
Time from onset of symptoms
not adequately controlled or ad-
justed for. All participants with
time fromonset of symptoms to
diagnosis < 7 days received rib-
avirin unless contraindicated
Both time from onset of symp-
toms and clinical contraindica-
tion are prognostic factors that
predict whether the individual
Serious
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Table 3. ROBINS-I assessment Dokuzoguz 2013 (Continued)
receives the intervention
Bias in selection of partici-
pants into the study
Mortality, length of hospital
stay, transfusion, withdrawal of
treatment: serious risk of bias
Control group selected by in-
cluding patients with time from
onset of symptoms to diagnosis
> 7 days and clinical contraindi-
cation to ribavirin
Both time from onset of symp-
toms and clinical contraindica-
tion are prognostic factors that
predict whether the individual
receives the intervention
Analysis was performed per
protocol (2 participants in con-
trol group were intended to be
treatedwith ribavirin but due to
gastrointestinal bleeding were
unable to receive oral medica-
tion)
Serious
Bias in classification of inter-
ventions
All outcomes Interventions well-defined in
Methods section
Low
Bias due to deviations from
intended interventions
All outcomes No deviation from intervention
not expected in normal practice
Low
Bias due to missing data All outcomes Somemissing outcome data not
dealt with in text. This is re-
lated to numbers of participants
receiving co-administration of
corticosteroids with ribavirin
Unbalanced across groups
Serious
Bias in selection of the re-
ported result
All outcomes Analysis was performed per
protocol. (2 participants in con-
trol group were intended to
be treated with ribavirin but
due to gastrointestinal bleeding
were unable to receive oral med-
ication). Effect of ribavirin as
measured will be overestimated
compared to intention-to-treat
analysis
Serious
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Table 4. ROBINS-I assessment: Elaldi 2009
ROBINS-I assessment
Reference: Elaldi 2009
Risk of bias domain Assessments by outcome Comment Conclusion
Bias due to confounding Mortality, length of hospital
stay, transfusion, withdrawal of
treatment: Serious risk of bias
due to baseline confounding
Baseline characteristics estab-
lished and are similar between
groups for severity of disease
and time from onset of symp-
toms to admission
Dif-
ferences occur between groups
in rates of maculopapular rash,
hepatomegaly and lactate dehy-
drogenase. None of these are
markers of disease severity un-
less petechiae were misclassified
as maculopapular rash
Use of historical control arm at
the onset of an epidemic estab-
lishes a difference in the qual-
ity of supportive care between
groups. As the time elapsed was
only one year we classified this
as serious and not critical con-
founding
No participants diagnosed re-
ceived ribavirin in the historical
control group All participants
diagnosed received ribavirin in
the intervention group
Nomethod to adjust for poten-
tial confounders reported
Serious
Bias in selection of partici-
pants into the study
Mortality, length of hospital
stay, transfusion, withdrawal of
treatment
Selection into study was not re-
lated to intervention, outcome
or any prognostic factor
Historical control group may
confound results as set out
above
It appears that all potential par-
ticipants for the specified study
years have been included in the
studies for the particular treat-
ment groups
Serious
Bias in classification of inter-
ventions
All outcomes Interventions well-defined in
Methods section
Low
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Table 4. ROBINS-I assessment: Elaldi 2009 (Continued)
Bias due to deviations from
intended interventions
All outcomes No information reported on ad-
herence of participants to rib-
avirin treatment schedule. For
supportive care: “Same pro-
portions of patients received
ES (12%) and FFP (39%) in
treated and untreated groups.
On the other hand,
more patients in the treated
group were infused with PS
(52%) than those in the un-
treated group (42%).” No other
information provided about co-
interventions
Low
Bias due to missing data All outcomes: serious All data appear to be reported Low
Bias in selection of the re-
ported result
All outcomes Unclear selection criteria for
establishing baseline similari-
ties between groups. PT/APTT
may be missing from baseline
characteristics
Reported results are in keeping
with those specified in the study
methods
Low
Table 5. ROBINS-I assessment: Izadi 2009
ROBINS-I assessment
Reference: Izadi 2009a
Risk of bias domain Assessments by outcome Comment Conclusion
Bias due to confounding Mortality, length of hospital
stay, transfusion, withdrawal of
treatment: serious risk of bias
due to baseline confounding
Time from onset of symptoms
adjusted for by stratification
into early/late ribavirin Baseline
characteristics and severity of
disease are not assessed, mea-
sured or controlled for
Multiple
regression models used to iden-
tify factors predictive of mortal-
ity. Regression does not adjust
for severity and prognostic fac-
tors for the efficacy of ribavirin
Adjusted estimates of effect not
Serious
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Table 5. ROBINS-I assessment: Izadi 2009 (Continued)
included in analysis due to
linear regression not outlined
clearly, although it is unlikely to
control for confounding of the
effect of ribavirin
Bias in selection of partici-
pants into the study
Mortality, length of hospital
stay, transfusion, withdrawal of
treatment: low risk of bias
Unclear if selection into the
study was based on partici-
pant’s characteristics observed
after the start of the study; ret-
rospective design
Moderate
Bias in classification of inter-
ventions
All outcomes Not recorded Moderate
Bias due to deviations from
intended interventions
All outcomes No deviation from intended in-
tervention, as would be the case
in usual practice. Most partic-
ipants received a transfusion -
Table 3 shows the proportions
of participants who received a
transfusion of platelet concen-
trates, and in some cases fresh
frozen plasma and packed ery-
throcytes. No other aspects of
care or co-interventions are dis-
cussed No information on ad-
hering to ribavirin treatment
Low
Bias due to missing data All outcomes: serious Outcome data (mortality or
cured) reported for all 63 par-
ticipants according to treatment
group
Low
Bias in selection of the re-
ported result
All outcomes Although no protocol avail-
able or prespecified outcomes,
the authors state that they at-
tempted to assess the effect of
ribavirin in reducing mortality
Moderate
Table 6. ROBINS-I Interpretation of domain level and overall risk of bias judgements
Judgement Within each domain Across domains Criterion
Low risk of bias The study is comparable to a well-
performed randomised trial with
regard to this domain
The study is comparable to a well-
performed randomised trial
The study is judged to be at low
risk of bias for all domains
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Table 6. ROBINS-I Interpretation of domain level and overall risk of bias judgements (Continued)
Moderate risk of bias The study is sound for a non-ran-
domized study with regard to this
domain but cannot be considered
comparable to a well-performed
randomised trial
The study provides sound evi-
dence for a non-randomized study
but cannot be considered com-
parable to a well-performed ran-
domised trial
The study is judged to be at low
or moderate risk of bias for all do-
mains
Serious risk of bias the study has some important
problems in this domain
The study has some important
problems
The study is judged to be at serious
risk of bias in at least one domain,
but not at critical risk of bias in
any domain
Critical risk of bias the study is too problematic in this
domain to provide any useful ev-
idence on the effects of interven-
tion
The study is too problematic to
provide any useful evidence and
should not be included in any syn-
thesis
The study is judged to be at critical
risk of bias in at least one domain
No information No information on which to base
a judgement about risk of bias for
this domain
No information on which to base
a judgement about risk of bias
There is no clear indication that
the study is at serious or critical
risk of bias and there is a lack of in-
formation in one or more key do-
mains of bias (a judgement is re-
quired for this)
Reproduced from Sterne 2016.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
One additional review author joined the review author team (Nicholas Henschke).
We restructured the Background to the review to add clarity.
We also included studies that compared early to late administration of ribavirin. This is an important part of the debate around the
effectiveness of ribavirin as a treatment. We allowed definitions of ‘early’ and ‘late’ to be determined by the study authors.
We did not include any cohort studies without comparators.
We allowed studies that had co-interventions other than ribavirin, as long as the indications were the same across all arms of the study.
We clarified that the outcome of death amongst those receiving ribavirin early versus late was a separate comparison, but mortality was
still the primary outcome.
We amended the prespecified subgroup analyses. We removed early versus late ribavirin as a subgroup and instead included it as a
comparison. This was because it required different study designs.
In our protocol we stated that wherever possible we would combine adjusted measures of effect for non-randomized studies. One
study, Dokuzoguz 2013, used a model to control for confounding of effect due to severity of disease. This resulted in an adjusted OR
of 0.04 (0.004 to 0.48), which is an extremely large effect. The small sample size, the size of the adjusted effect, missing data from
the corticosteroid analysis, concerns about unmeasured confounding factors such as time from onset of symptoms, and the fact that
the study analysed severe patients with gastro-intestinal haemorrhage per protocol and not by intention-to-treat meant that we took a
conservative approach to synthesis and presented the non-adjusted stratified data in a forest plot instead of the adjusted estimate.
We also only included cohort studies if they had more than 10 participants.
59Ribavirin for treating Crimean Congo haemorrhagic fever (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
